Home
Heart Failure

Heart Failure

Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round

Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund

1.00 EBAC

Published: 22/10/2024

Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
Select appropriate patients for advanced medical therapy
Recall recent trial data for novel therapeutic approaches
Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches

Philip Hawkins Marianna Fontana Paolo Milani et al

1.00 EBAC

Published: 19/07/2024

Understand the nature of amyloidosis and its effects on various organs, particularly the heart
Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team

Advancing Patient Care in Hypertrophic Cardiomyopathy

Ahmad Masri Caroline Coats

0.50 AMA PRA Credit

Published: 28/06/2024

Recall recent trial data for novel disease modifying therapy in HCM
Describe the evolving guideline directed approach to managing HCM
Develop an expert-led approach to implementing novel therapy in clinical practice

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

Antoni Bayés-Genís Lisa Anderson Stephen J Greene

Not accredited

Published: 03/06/2024

Recall guideline recommendations for the use of NT-proBNP in heart failure
Describe current practices in heart failure diagnosis and the impact on treatment outcomes
Develop an optimised approach to the timely diagnosis and management of heart failure

An Expert Approach to Cardio-Renal Protection in CKD

James Burton Navdeep Tangri David Wheeler et al

2.00 EBAC

Published: 26/06/2024

Recall clinical evidence and guidelines for the management of CKD patients without diabetes
Describe current gaps and barriers in evidence-based management for CKD without diabetes
Apply evidence based-management strategies to a case study
Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Implementing Heart Failure Guidelines with Collaborative Care

Carolyn Lam Mark Petrie Stephen J Greene et al

Not accredited

Published: 15/09/2023

Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
Apply latest guideline recommendations to patient cases
Describe barriers preventing early initiation of GDMT
Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
Identify the importance of the nurse/cross-functional team

Heart Failure

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

Antoni Bayés-Genís Lisa Anderson Stephen J Greene

Not accredited

Published: 03/06/2024

Recall guideline recommendations for the use of NT-proBNP in heart failure
Describe current practices in heart failure diagnosis and the impact on treatment outcomes
Develop an optimised approach to the timely diagnosis and management of heart failure

Advancing Patient Care in Hypertrophic Cardiomyopathy

Ahmad Masri Caroline Coats

0.50 AMA PRA Credit

Published: 28/06/2024

Recall recent trial data for novel disease modifying therapy in HCM
Describe the evolving guideline directed approach to managing HCM
Develop an expert-led approach to implementing novel therapy in clinical practice

An Expert Approach to Cardio-Renal Protection in CKD

James Burton Navdeep Tangri David Wheeler et al

2.00 EBAC

Published: 26/06/2024

Recall clinical evidence and guidelines for the management of CKD patients without diabetes
Describe current gaps and barriers in evidence-based management for CKD without diabetes
Apply evidence based-management strategies to a case study
Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches

Philip Hawkins Marianna Fontana Paolo Milani et al

1.00 EBAC

Published: 19/07/2024

Understand the nature of amyloidosis and its effects on various organs, particularly the heart
Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team

Examining a Complex Heart Failure Case

Andrew JS Coats Katherine Tuttle Richard Hobbs et al

1.00 EBAC

Published: 10/03/2023

Identify individuals likely to have HFpEF from initial presentation
Refer suspected individuals for specialist assessment
Initiate GDMT for HF as soon as patients are stable
Initiate GDMT in HF regardless of EF and phenotype
Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists

Heart Failure Management in a Changing Paradigm

Andrew JS Coats Shelley Zieroth Javed Butler et al

1.00 EBAC

Published: 16/06/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
Incorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

Heart Failure

Incorporating GDMT and PRO Endpoints for Personalised HF Management

Andrew JS Coats Mikhail Kosiborod Shelley Zieroth et al

1.00 EBAC

Published: 23/03/2023

Review current GDMT in HFrEF and HFpEF
Describe the relationship between initiation of GDMT and HF outcomes
Prescribe GDMT according to current international recommendations
Recall the elements of the Kansas City Cardiomyopathy Questionnaire
Describe the clinical studies that support the use of functional and QoL measures in practice
Initiate quality of life and functional improvement measures in routine practice
Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
Adopt shared decision-making with HF patients

Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time

Marc Dweck Milind Y Desai Carolyn Ho et al

1.00 EBAC

Published: 06/02/2023

Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
Select appropriate imaging modalities to facilitate accurate risk stratification
Stratify patients based on specific risk features and disease severity
Choose suitable treatment modalities for patients based on specific disease features and severity

Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021

Perry Elliott

0.50 AMA PRA Credit

Published: 04/11/2021

Identify patients likely to benefit from invasive procedures versus pharmacological treatment
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Examining a Complex Heart Failure Case

Andrew JS Coats Katherine Tuttle Richard Hobbs et al

1.00 EBAC

Published: 10/03/2023

Identify individuals likely to have HFpEF from initial presentation
Refer suspected individuals for specialist assessment
Initiate GDMT for HF as soon as patients are stable
Initiate GDMT in HF regardless of EF and phenotype
Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Carolyn Ho

0.75 AMA PRA Credit

Published: 17/02/2022

Recall the efficacy and safety of existing HCM treatments
Summarise results from ongoing trials with experimental treatments
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

James Burton Shelley Zieroth Clara Bonanad Lozano et al

Not accredited

Published: 16/05/2023

Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
Identify patients who would benefit from anti-hyperkalaemia medications
Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
Summarise current guideline recommendations on the use of potassium binding agents

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives